Skip to main content

Table 4 Adverse and serious adverse events

From: The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial

Placebo IL-1Ra
Fluctuating GCS Raised ICP; hypotensiona
Desaturation; cardiac arrhythmia; meningitis Chest sepsis; focal seizures cardiac arrhythmia; increased urine output; increased CRPa
IV line infection; chest infection; focal seizure Ventilator-associated pneumonia
Leaking wounda  
Acute agitationa; pyrexia of unknown origina  
  1. aThe 18 adverse and serious adverse events are shown for the five participants that received placebo and the three that received IL-1Ra, in whom they occurred. CRP, C-reactive protein; GCS, Glasgow Coma Scale; ICP, intracranial pressure; IL-1Ra, interleukin-1 receptor antagonist; IV, intravenous.